Not Available.
10.1016/j.apsb.2023.07.020
- Author:
Chunhao ZHU
1
;
Xiaobing LAN
1
;
Zhiqiang WEI
2
;
Jianqiang YU
1
;
Jian ZHANG
1
Author Information
1. School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
2. Medicinal Chemistry and Bioinformatics Center, Ocean University of China, Qingdao 266100, China.
- Publication Type:Review
- From:
Acta Pharmaceutica Sinica B
2024;14(1):67-86
- CountryChina
- Language:English
-
Abstract:
Neuropathic pain is a debilitating pathological condition that presents significant therapeutic challenges in clinical practice. Unfortunately, current pharmacological treatments for neuropathic pain lack clinical efficacy and often lead to harmful adverse reactions. As G protein-coupled receptors (GPCRs) are widely distributed throughout the body, including the pain transmission pathway and descending inhibition pathway, the development of novel neuropathic pain treatments based on GPCRs allosteric modulation theory is gaining momentum. Extensive research has shown that allosteric modulators targeting GPCRs on the pain pathway can effectively alleviate symptoms of neuropathic pain while reducing or eliminating adverse effects. This review aims to provide a comprehensive summary of the progress made in GPCRs allosteric modulators in the treatment of neuropathic pain, and discuss the potential benefits and adverse factors of this treatment. We will also concentrate on the development of biased agonists of GPCRs, and based on important examples of biased agonist development in recent years, we will describe universal strategies for designing structure-based biased agonists. It is foreseeable that, with the continuous improvement of GPCRs allosteric modulation and biased agonist theory, effective GPCRs allosteric drugs will eventually be available for the treatment of neuropathic pain with acceptable safety.
